复旦大学
Fudan University
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 80 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 13
- 牵头的研究论文
- 80
- 牵头的试验
- 44
- 占中国试验的比例
- 7.4%
- 占全球论文的比例
- 2.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial.
- Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.
- LINC-PINT expression and rs1059698 polymorphism associate with chemoradiotherapy efficacy in Chinese nasopharyngeal carcinoma patients.
- Mucosal Flap Reconstruction Enhances Survival in Salvage Endoscopic Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma: A Propensity-Matched Cohort Study.
- Artificial intelligence-assisted detection of nasopharyngeal carcinoma on endoscopic images: a national, multicentre, model development and validation study.
ClinicalTrials.gov 上的试验6
- Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma
- Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
- Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
- Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
- Adjuvant vs Surgery Only in Early-stage Recurrent NPC
- Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 109 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 17
- 牵头的研究论文
- 109
- 牵头的试验
- 53
- 占中国试验的比例
- 9.3%
- 占全球论文的比例
- 2.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
- Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
- Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Cli
- Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma.
- Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.
ClinicalTrials.gov 上的试验6
- PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
- Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
- CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
- Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 603 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 20
- 牵头的研究论文
- 603
- 牵头的试验
- 107
- 占中国试验的比例
- 7.3%
- 占全球论文的比例
- 2.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
- External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial.
- 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation.
- Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.
- Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.
ClinicalTrials.gov 上的试验6
- Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
- The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 281 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 39
- 牵头的研究论文
- 281
- 牵头的试验
- 88
- 占中国试验的比例
- 6.0%
- 占全球论文的比例
- 1.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).
- Nutritional support after hospital discharge reduces long-term mortality in patients after gastric cancer surgery: Secondary analysis of a prospective randomized trial.
- Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01).
- Early intravenous branched-chain amino acid-enriched nutrition supplementation in older patients undergoing gastric surgery: a randomized clinical trial.
- First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
ClinicalTrials.gov 上的试验6
- An Observational Study on Gastric Cancer in High-risk Individuals
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
- A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
- Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
肝母细胞瘤
Hepatoblastoma2021–2025年中国大陆共有 154 篇该病的 PubMed 英文论文,这里牵头了其中 8 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(13.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 8
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 1.8%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.
- Single-cell profiles delineate immune cell remodeling and enhanced tumor-fibroblast interaction of hepatoblastoma after chemotherapy.
- YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.
- ACSL4 promotes the formation of the proliferative subtype in hepatoblastoma.
- Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis.
视网膜母细胞瘤
Retinoblastoma2021–2025年中国大陆共有 301 篇该病的 PubMed 英文论文,这里牵头了其中 7 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 3
- 牵头的研究论文
- 7
- 牵头的试验
- 3
- 占中国试验的比例
- 23.1%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study.
- Assessment of Retinal Microvasculature and Choroidal Vascularity After Intra-arterial Chemotherapy for Retinoblastoma.
- Quantitative evaluation of retinal microvasculature and retrobulbar vessels after intravenous chemotherapy for retinoblastoma.
- Low expression of NR1D1 and NR2E3 is associated with advanced features of retinoblastoma.
- Multimodal Imaging of a Retinocytoma.
ClinicalTrials.gov 上的试验4
- High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
- Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
- Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
- G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
脊索瘤
Chordoma2021–2025年中国大陆共有 105 篇该病的 PubMed 英文论文,这里牵头了其中 8 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 8
- 牵头的试验
- 1
- 占中国试验的比例
- 16.7%
- 占全球论文的比例
- 1.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Soft-tissue reconstruction with pedicled vertical rectus abdominis myocutaneous flap after total or high sacrectomy for giant sacral tumor.
- Primary Skull Base Chordomas: A Clinicopathological Analysis of 94 Patients.
- Association of radical vs palliative resection of spinal chordoma with survival: a population-based study.
- How I do it? Resection of residual petrous apex chordoma with combined endoscopic endonasal and contralateral transmaxillary approaches.
- Ubiquitin-independent pathway regulates the RIT1-MAPK pathway in chordoma progression.
ClinicalTrials.gov 上的试验1
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 26 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 26
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?
- Peri-osteosarcoma adipose computed tomography attenuation and volume for predicting chemotherapy response in pediatric patients.
- ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma.
- Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.
- Establishment and characterization of a patient-derived metastatic extraskeletal Ewing sarcoma cell line ES-ZSS-1.
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025年中国大陆共有 523 篇该病的 PubMed 英文论文,这里牵头了其中 30 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 30
- 牵头的试验
- 1
- 占中国试验的比例
- 1.4%
- 占全球论文的比例
- 1.8%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.
- Proteomic Characterization Identifies Clinically Relevant Subgroups of Gastrointestinal Stromal Tumors.
- Endoscopic resection for small rectal gastrointestinal stromal tumors: a pilot study.
- Hidden risk factors for recurrence of jejunoileal Gastrointestinal stromal tumors with low NIH classification: implications for surveillance and adjuvant therapy.
- A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration.
ClinicalTrials.gov 上的试验6
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- RCT of EFTR Versus STER for GIST Treatment
- A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST
- Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
神经母细胞瘤
Neuroblastoma2021–2025年中国大陆共有 1,132 篇该病的 PubMed 英文论文,这里牵头了其中 20 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.8%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 20
- 牵头的试验
- 1
- 占中国试验的比例
- 2.4%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Deep learning models for differentiating three sinonasal malignancies using multi-sequence MRI.
- The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching.
- Survival Analysis and Prognostic Factors After Endonasal Resection of Advanced Olfactory Neuroblastomas: A Single Institution Experience.
- Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.
- Incidental Neuroblastoma.
ClinicalTrials.gov 上的试验3
尤文肉瘤
Ewing sarcoma2021–2025年中国大陆共有 163 篇该病的 PubMed 英文论文,这里牵头了其中 8 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 8
- 牵头的试验
- 2
- 占中国试验的比例
- 12.5%
- 占全球论文的比例
- 0.7%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?
- Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.
- Establishment and characterization of a patient-derived metastatic extraskeletal Ewing sarcoma cell line ES-ZSS-1.
- Clinicopathological characteristics and genetic features of young and senior Ewing sarcoma patients.
- Gastrointestinal Ewing Sarcoma: A Clinicopathological and Molecular Genetic Analysis of 25 Cases.
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 37 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 4
- 牵头的研究论文
- 37
- 牵头的试验
- 5
- 占中国试验的比例
- 1.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Real-World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15-Year Period.
- Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study.
- Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.
- Enhanced clinical outcomes with radiotherapy in diagnostically challenging intracranial plasmacytomas: Analysis of 190 cases.
- IgE-kappa multiple myeloma with kappa free light chain: a case report.
ClinicalTrials.gov 上的试验6
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Longitudinal Data Registry of Plasma Cell Dyscrasia
- The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia (B-ALL)2021–2025年中国大陆共有 225 篇该病的 PubMed 英文论文,这里牵头了其中 0 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 0
- 牵头的试验
- 1
- 占中国试验的比例
- 0.4%
- 占全球论文的比例
- 0.0%
ClinicalTrials.gov 上的试验6
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
- Phase Ib Clinical Study of Keynatinib
- Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
再生障碍性贫血
Aplastic anaemia2021–2025年中国大陆共有 412 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(17.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- Mendelian randomization of circulating proteome identifies IFN-γ as a druggable target in aplastic anemia.
- Monocytic myeloid-derived suppressive cells mitigate over-adipogenesis of bone marrow microenvironment in aplastic anemia by inhibiting CD8+ T cells.
- Effects of cimetidine on ciclosporin population pharmacokinetics and initial dose optimization in aplastic anemia patients.
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis (HLH)2021–2025年中国大陆共有 399 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 1
- 占中国试验的比例
- 2.1%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验3
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
β 地中海贫血
Beta thalassaemia2021–2025年中国大陆共有 312 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.9%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 2
- 牵头的试验
- 2
- 占中国试验的比例
- 4.3%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验4
- A Long-term Follow-up Study in Participants Who Received CS-101
- Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major
- A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
- A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder (NMOSD)2021–2025年中国大陆共有 485 篇该病的 PubMed 英文论文,这里牵头了其中 23 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.5%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 23
- 牵头的试验
- 2
- 占中国试验的比例
- 2.6%
- 占全球论文的比例
- 1.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
- Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.
- Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.
- Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.
- KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.
ClinicalTrials.gov 上的试验6
- HANDLE-a Real World Study on Satralizumab in NMOSD
- A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
- BLAZE-Limiting Approach in NMOSD
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
- An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
IgG4相关性疾病
IgG4-related disease2021–2025年中国大陆共有 246 篇该病的 PubMed 英文论文,这里牵头了其中 6 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.1%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 6
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Immunoglobulin G4-related sclerosing mastitis: MRI findings and the literature review.
- Clinical and pathological predictors of relapse in IgG4-related disease.
- Pathological count of IgG4-positive plasmacytes suggests extraophthalmic involvement and relapse in patients with IgG4-related ophthalmic disease: a retrospective study.
- Heart Transplantation for a Rare Case of Immunoglobulin G4-related Cardiac Pseudotumor.
- Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study.
重症肌无力
Myasthenia gravis2021–2025年中国大陆共有 499 篇该病的 PubMed 英文论文,这里牵头了其中 33 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.6%)相比。
- 牵头的开放试验
- 5
- 牵头的研究论文
- 33
- 牵头的试验
- 7
- 占中国试验的比例
- 7.6%
- 占全球论文的比例
- 1.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.
- Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.
- The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.
- Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.
- Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.
ClinicalTrials.gov 上的试验6
- EFG vs IVIG in TAMG
- An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Myasthenia Gravis Registry in China
- Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
- Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
- An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
烟雾病
Moyamoya disease2021–2025年中国大陆共有 356 篇该病的 PubMed 英文论文,这里牵头了其中 24 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.9%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 24
- 牵头的试验
- 3
- 占中国试验的比例
- 9.1%
- 占全球论文的比例
- 1.9%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Inhalational versus intravenous anesthetic for cerebrovascular accident outcomes after surgical revascularization for adult moyamoya disease.
- Post-anesthesia care unit delirium in children with moyamoya disease undergoing indirect revascularization: incidence and risk factors.
- The cerebellar glucose metabolism in moyamoya vasculopathy and its correlation with neurocognitive performance after cerebral revascularization surgery: a [18F]FDG PET study.
- Individualised evaluation based on pathophysiology for moyamoya vasculopathy: application in surgical revascularisation.
- Transient ischemic attack after indirect revascularization surgery for pediatric patients with moyamoya disease: A retrospective study of intraoperative blood pressure.
ClinicalTrials.gov 上的试验5
- Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Registry of Multicenter Brain-Heart Comorbidity in China
- Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery
- The Adult Hemorrhagic Moyamoya Surgery Study
肝豆状核变性(Wilson 病)
Wilson disease2021–2025年中国大陆共有 201 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(7.5%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
ClinicalTrials.gov 上的试验1
胆道闭锁
Biliary atresia2021–2025年中国大陆共有 214 篇该病的 PubMed 英文论文,这里牵头了其中 21 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.8%)相比。
- 牵头的开放试验
- 3
- 牵头的研究论文
- 21
- 牵头的试验
- 4
- 占中国试验的比例
- 20.0%
- 占全球论文的比例
- 2.8%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Effect of Adjuvant Steroid Therapy in Type 3 Biliary Atresia: A Single-Center, Open-Label, Randomized Controlled Trial.
- Preventive effect of prophylactic intravenous antibiotics against cholangitis in biliary atresia: a randomized controlled trial.
- Development and validation of a minimally invasive diagnostic model for biliary atresia using artificial intelligence.
- Establishment of Biliary Atresia Prognostic Classification System via Survival-Based Forward Clustering - A New Biliary Atresia Classification.
- Incidence and outcome of biliary atresia in Shanghai, China from 2015 to 2016: a cohort study.
ClinicalTrials.gov 上的试验6
- Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
- Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
- High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
- A Peer Support Network System Construction for the Primary Caregivers of Children With Biliary Atresia
- Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025年中国大陆共有 264 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- Deciphering the molecular landscape of NMDAR-E associated ovarian teratomas: a Multi-Omics approach.
- Brain MRI features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis secondary to central nervous system infection in adult patients.
- Performance of the clinical assessment scale for autoimmune encephalitis in a pediatric autoimmune encephalitis cohort.
大动脉炎
Takayasu arteritis2021–2025年中国大陆共有 187 篇该病的 PubMed 英文论文,这里牵头了其中 37 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(24.6%)相比。
- 牵头的开放试验
- 2
- 牵头的研究论文
- 37
- 牵头的试验
- 6
- 占中国试验的比例
- 24.0%
- 占全球论文的比例
- 4.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
- Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. Reply.
- PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study.
- Comment on: A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study: reply.
- Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.
ClinicalTrials.gov 上的试验6
- A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
- A Pilot Study in Severe Patients With Takayasu Arteritis.
- Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
- Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
- Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis
- The Registry Study of Takayasu Arteritis in East China
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025年中国大陆共有 989 篇该病的 PubMed 英文论文,这里牵头了其中 18 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 18
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects.
- Physical activity and idiopathic pulmonary fibrosis: A prospective cohort study in UK Biobank and Mendelian randomization analyses.
- Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.
- Baicalin inhibits the Akt/mTOR/ULK1 signaling pathway to activate autophagy and ameliorate pulmonary fibrosis.
- Iron dysregulation and ferroptosis are associated with pulmonary fibrosis: Insight from idiopathic pulmonary fibrosis, systemic sclerosis, and COVID-19 patients.
ClinicalTrials.gov 上的试验6
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 22 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 22
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Dysregulation of extracellular potassium distinguishes healthy ageing from neurodegeneration.
- Brain region-specific synaptic function of FUS underlies the FTLD-linked behavioural disinhibition.
- A new ERBB4 variant in amyotrophic lateral sclerosis type 19: Case report and review of the literature.
- Iron quantitative analysis of motor combined with bulbar region in M1 cortex may improve diagnosis performance in ALS.
- Integrated profiling of iPSC-derived motor neurons carrying C9orf72, FUS, TARDBP, or SOD1 mutations.
ClinicalTrials.gov 上的试验1
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025年中国大陆共有 55 篇该病的 PubMed 英文论文,这里牵头了其中 16 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(29.1%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 16
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 2.9%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Teaching NeuroImages: Hirayama Disease With Symmetric Atrophy of Bilateral Distal Upper Extremities.
- Effectiveness and safety of Risdiplam for types 1-3 spinal muscular atrophy in a single center.
- Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.
- Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
- The role of leisure-time physical activity in maintaining cervical lordosis after anterior cervical fusion and its impact on the motor function in patients with hirayama disease: a retrospective cohort analysis.
ClinicalTrials.gov 上的试验6
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
- Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
- Adult Spinal Muscular Atrophy (SMA) China Registry
- Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
法布雷病
Fabry disease2021–2025年中国大陆共有 73 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.3%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 1
- 牵头的试验
- 2
- 占中国试验的比例
- 14.3%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
庞贝病
Pompe disease2021–2025年中国大陆共有 30 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.7%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 1
- 占中国试验的比例
- 11.1%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025年中国大陆共有 213 篇该病的 PubMed 英文论文,这里牵头了其中 4 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 4
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文4
- Pseudoexon activating by a deep intronic variant and phenotype variation in a Chinese family with dystrophinopathy.
- Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021.
- Acute hepatotoxicity of intravenous amiodarone in a Becker muscular dystrophy patient with decompensated heart failing and ABCB4 gene mutation: as assessed for causality using the updated RUCAM.
- Two novel deep intronic variants cause Duchenne muscular dystrophy by splice-altering mechanism.
ClinicalTrials.gov 上的试验4
- Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
- Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
- A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy
- Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
白塞病
Behçet disease2021–2025年中国大陆共有 245 篇该病的 PubMed 英文论文,这里牵头了其中 28 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 28
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 2.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'.
- Massive lower gastrointestinal bleeding due to rupture of the superior mesenteric artery branch in Behçet's disease: case report.
- Clinical features of cardiac and vascular involvements in Behçet's syndrome: a cross-sectional study from Shanghai Behçet's syndrome database.
- A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well-Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease.
- Autoinflammatory syndromes mimicking Behçet's disease with gastrointestinal involvement: a retrospective analysis.
ClinicalTrials.gov 上的试验1
IgA 肾病
IgA nephropathy2021–2025年中国大陆共有 736 篇该病的 PubMed 英文论文,这里牵头了其中 14 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 14
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.8%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Exploring the shared molecular mechanisms of primary hypertension and IgA vasculitis through a case report and combining bioinformatics analysis.
- Serum soluble interleukin-2 receptor alpha may predict tubulointerstitial inflammatory cell infiltration and short-term disease progression in immunoglobin A nephropathy.
- Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study.
- Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.
- IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway.
ClinicalTrials.gov 上的试验6
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
- A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
- Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
成骨不全症
Osteogenesis imperfecta2021–2025年中国大陆共有 99 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(17.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
先天性巨结肠
Hirschsprung disease2021–2025年中国大陆共有 161 篇该病的 PubMed 英文论文,这里牵头了其中 4 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(13.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 4
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文4
- Aberrant high expression of the TET1 gene in Hirschsprung's disease.
- Skip segment Hirschsprung's disease: report of two rare cases and management.
- Serum Metabolomic Signatures of Hirschsprung's Disease Based on GC-MS and LC-MS.
- Intestinal fibrosis in aganglionic segment of Hirschsprung's disease revealed by single-cell RNA sequencing.
遗传性大疱性表皮松解症
Inherited epidermolysis bullosa2021–2025年中国大陆共有 56 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.5%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases.
- A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
- Staphylococcus aureus Promotes Cutaneous Lesions in Patients With Epidermolysis Bullosa.
- Treatment of epidermolysis bullosa simplex with dupilumab.
- Generation of the induced pluripotent stem cell line (ZSPHARi001-A) from a patient with recessive dystrophic epidermolysis bullosa carrying compound heterozygous mutation in the COL7A1 gene.
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025年中国大陆共有 59 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 1
- 占中国试验的比例
- 33.3%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。